Recruiting
Phase 1
Phase 2

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sponsor:

Aptose Biosciences Inc.

Code:

NCT03850574

Conditions

Leukemia, Myeloid, Acute

Refractory AML

Relapsed Adult AML

Myelodysplastic Syndrome with Excess Blasts-2

Chronic Myelomonocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tuspetinib

Venetoclax Oral Tablet

Azacitidine for Intravenous Infusion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information